Member Info for HedgeHogarth

Unfortunately - money brings out the worst in people.

At the current market cap, with Hemo assets and the timing there is a potential huge opportunity here.

Hemo are on the final straight towards clinical trials.

good luck everyone

Full of the brown stuff

Let's hope Vlad releases the RNS and I will enjoy seeing them burn

Vlad's tweet says nothing we did not know - they are working very hard to commence trials ASAP. There may or may not be an RNS this coming week. But we all know that it could come anytime now.

As for the SP - with less than 0.5% shares transacted daily - the SP reflects the actions of a small minority of people.

When (not IF) the volume increases on news or speculation the share price will move very quickly. If the news or speculation is good, great or outstanding - nobody will be able to buy at 2p!

I won't lie - i don't like seeing the SP at this level - but when I reflect on it more broadly - it's not that important to me. It's simply the price i need to pay to top-up. I'm more interested in what the SP will be in 2,3,4.6 months time - when funding sorted, when trials started, when initial safety data starts flowing, when CBR moves closer to trials.

A very rare post from me.

It is embarrassing reading some of the drivel on here

The most recent RNS CLEARLY STATES that the expectation is to commence trials in 2023; NOTHING HAS CHANGED

Back in June/July when the CH was applied - my expectation was that it would be lifted in November. It felt a long time away (at the time) but is now rapidly approaching. Nothing has changed for me and I still think that November is a good bet to see the CH lifted.

Vlad's response on Twitter is 100% vague, as i would expect. I have no idea why this board thinks there would be on RNS on Monday - it is either a guess or insider information. Could there be an RNS on Monday - yes of course there could be. There could be an RNS anytime now given the impending news flow. Nothing that Vlad has said on Twitter changes that - he'd hardly say "Looks like you are in luck Fonzie - there will be an exciting RNS on Tuesday"

One2one is a Trader with a clear history of betting against the share price. His provocative posts have be proved on so many occasions to be full of the brown stuff. His ridiculous posts about 2024 are there to create doubt - but they are as genuine as his posts 2 weeks ago that a placing would be announced imminently

Shareholders may be tempted to build on the downward momentum - sell a few blocks now and buy back more shares on the assumption that the SP drops below 2p. This is a VERY dangerous game from my experience; anyone selling now at 2p would need the ASK to drop from the current 2.1p to 1.8p to make it worthwhile. Yet you don't know what price the Traders will be closing positions - my guess is that traders sold at 2.2-2.3p so I imagine they will be all over the ASK if it dropped to 1.8p. So it is unlikely to stay there for long and the poor LTH may find themselves achieving the opposite of what they hoped.

I'm holding onto my shares with a tight grip and a patient mindset...

Clinical trials are just weeks away now - the only "FACT" that indicates the timing of the start of trials is the last Hemo RNS that states they 'expect' to commence in 2023. i.e. Hemo's best view is 2023. Ofcourse there is a possibility that they may slip into Q1 - but that is only a couple of months away which is nothing in Biotech terms. Hemo are now on the cusp of transformation and promotion to a clinical Biotech.

We also know that CBR is in great shape given it was pitched in September to >100 serious Biotech investors. Prevail are hugely experienced and experts in Biotech - they now have skin in the game and will be working very closely with Hemogenyx on funding plans. (Go check out their record of picking winners and the scrutiny of their duel diligence and selection process)

Good luck all and be very careful if you choose to give any credence to the narratives of Stu and One2one. Their motives are very clear - One2one has clearly stated he/she is looking for the shareprice to drop.

Also worth noting that the RNS on 27th Sept clearly states that the Indian partnership includes a working capital solution

The drop has been completed overdone.

This is a good company - that has made a good decision to pivot

At risk of sounding like a broken record.

I'm officially removing myself from this forum.

I've wasted too much time on here, it's not good for my metal health and I have better things to do.

I leave in a very positive frame of mind as I shared earlier.

Hemo is a significantly stronger and more valuable (in my eyes, regardless of mCap) than it was when I first noticed them.

Good luck everybody - I am convinced that holders will be rewarded,

I'm also hoping for the next RNS to arrive very soon on CBR. We are due an update

Bye Bye

Looks like Micky, DCT55 and Stu can have their own party one day.

Hopefully with Stu declared out and I assume Micky not far behind we can look forward to a forum with less manipulation (Stu) and less expletives and insults (Micky)

Nothing change for me.

You only lose money when you sell

The SP has only dipped 10-15 per cent. It is still 30 per cent higher than 3 weeks ago

The SP was sub 1.5p for a long time, so plenty of opportunity for people to have bought and been in profit on them. They could have sold at 2.6p for most of last week if they chose.

Those that those not to sell, like me, are hanging around for something much higher. Time will tell if we are right to do so.

Prevail are happy, I am happy x

So... A few emotional digs...

What have those posters read in the report that they were not expecting?

No surprises, as it should be

Inevitable reaction by a few traders and MMs more than happy to oblige as a cheeky 10-15% dip drives nice volume

Hemo doing all the right things.

GLA

One2one - the reason for the clinical hold is there for all to see in the RNS from Hemo RNS dated 10th July.

It is now September, and Hemo RNSd the following

Further to the announcement on 10 July 2023, Hemogenyx Pharmaceuticals carefully considered the comments provided by the FDA in connection with the CH and responded in August 2023 with a detailed plan, supported by laboratory tests, to address those comments. The Company has now received confirmation from the FDA that the Company's plan satisfactorily addresses the agency's comments.

I suggest you close you short position before it get even more expensive for you!

A rare moment of praise for Stu

Well done for posting something positive - I agree that the investment and partnership with Prevail is excellent news. The best bit for me is the comfort of knowing that they conducted such a thorough due diligence process before choosing to invest.

There you go - it was not hard was it. It is infinitely easier to post opinions that are realistic with a small dose of optimism

I'm assuming you are intelligent and your actions are very deliberate; so make it easier for yourself and stop swimming against the tide. Whether it suits your agenda or not, it's very likely that we will continue to see great updates from Hemo ahead of Phase 1 results. And we all agree that investing in small Biotechs is inherently risky and there is no guarantee that Hemo CAR-T will perform well in Phase 1 trials.

@Hemoknowlege

Stu is clutching at straws to suggest that he can create a narrative that Hemo CAR-T will not be cleared to start trials. And let's be clear - he is working on the same information that we all are which is:

FDA approved Hemo plan to address the issue that gave rise to the clinical hold

Hemo expect to commence clinical trials in FY23

Hemo have announced strategic partnership - something they said they would not do until FDA clearance

If he can even be bothered, he will probably try and make a play out of why the RNS only said preliminary tests or try to create some doubt as to whether Hemo will successfully complete the body of work.

If i was him, i would not even bother. We ALL know he has an obsession with conducting a worst case scenario - and we all know why he does it.

Most investors will be well aware that CAR-T is still an emerging technology; It has been a game change for the other most common form of Leukaemia (ALL) demonstrating remarkable success with an impressive 82% response rate in relapsed & refractory B-cell ALL

Hemogenyx's goal is to bring this success to Acute myeloid leukemia (AML). an aggressive, rapidly progressing blood cancer. The 5-year overall survival rate of AML is only 27%, accounting for approximately 2% of all cancer deaths in the United States. Patients are desperate for better outcomes

To date, CAR T-cells for AML has been challenging and there is no CAR-T therapy for AML signed off yet after all trial phases yet. For a number of reasons; identifying a suitable target and avoiding cytokine release syndrome.

Hemo know this and clearly believe that they have a solution that overcomes the problems that others that came before them faced. They have a target protein, FLT3 , patented for CAR-T. Hemo are confident from their pre-clincial tests that this target will overcome the problems that others have faced.

It is not just Hemogenyx that think so;

(1) the FDA have given the plan a green light and fed back positively

(2) Hemo's Medical Director and a committee of "Key Opinion Leaders" who are experts in the treatment of leukaemias have helped shaped the IND

(3) And don't forget that Hemo have been working with PENN univeristy and the team that got were the first to get full FDA approval for CAR-T. (Dr Carl June and team)

Now - lets discuss Phase 1 trials.

Firstly, let's remember what phase 1 trials aim to achieve. It's about ensuring the safety primarily - the biggest risk in Ph 1 is if a patient dies. Many Phase 1 trials also provide data on the efficacy. This will be the case with Hemo's trial as CAR-T will be tested on AML sufferers.

It's not really about PASS or FAIL. Phase 1 is an opportunity to learn about dosage and tolerances when given to humans.

Success is about learning enough to move into Phase 2 trials.

Given the challenges with CAR-T and AML - many stalled at Phase 1. However, please find below a a couple of CAR-T candidates (for AML) that successfully made it through Phase 1.

https://ashpublications.org/blood/article/130/22/2373/36556/Gemtuzumab-ozogamicin-for-acute-myeloid-leukemia

https://classic.clinicaltrials.gov/ct2/show/NCT03631576

Worth noting that when doing research - all the learning appear to point nicely towards the solution that Hemo will take into clinical trials. (i.e Finding a target that is not expressed or very minimally expressed in healthy tissue and there is encouraging with regards to FLT3 more broadly)

Warning - I'm not a scientist. So please take that into consideration when reading my posts. We should trust the talented team at Hemo, the FDA, our advisers and take notice of the through due diligence conducted by Prevail who are experts in this field.

Hemogenyx will be publishing their Interim Results either today or tomorrow. The report will focus mainly on the 6mth period ending 30th June FY23, with a few post period highlights.

Newflash - It will show a bigger loss year on year (in line with expectation)

I'm sure the trolls will try to make hay out of the loss which will appear significantly bigger YOY. However, it is nothing new or unexpected - Hemo are a pre-revenue Biotech who have moved to world class lab, increased their opex as they prepare for trials and the FY23 numbers are likely to include up to a £0.5m FX loss which is likely to reverse in H2.

Here's my expectations:

Loss of 'between £3m and £3,5m':

Significantly higher than FY22 of £1.14m due to FX Loss and additional costs related to taking CAR-T towards clinical trials (Lab, Equipment , Internal and External resources etc)

(This reflects Rent on the new Lab, Additional costs relating to Testing for IND Submission, Legal and consulting fees + an FX loss est. an £0.5m)

It may be less if Hemo are able to capitalise some of the additional expenses linked to CAR-T - I'm not familiar on accounting for R&D in early stage Biotechs.

The estimated FX loss of £0.5m is because the dollar depreciated from 0.81 (0.83 when they received the £4m raise) and ended the period on 0.79. As of 28 Sept, the Dollar as recovered so this is unlikely to be an issue in the FY Results and it will be offset in the H2 accounts as a gain.

Cash - c£4.5m at 30 June - including £4m raised in Jan/Feb. Post period, they will allude to the +£680k from Prevail

CAR-T - a great summary of the work in the 6mth to submit IND - and a post period update that further emphasises their expectation that Ph 1 trials can start in FY23

CBR - I imagine, we must get an update of the progress here - Hemo may even have to release a 2nd RNS to include any price sensitive update. We are due an update so hopefully we will learn more - failing that, they may re-iterate the current step.

CDX - Less certain here - I expect we will get something similar to the statement in the FY22 Final results. This is not Hemo's top priority right now. We know that Hemo are looking to take this into clincial trials; the work that Selexis are doing is key to that. However, Hemo are not aiming to fund it on their own - they are in ongoing discussion to move it forwards with partner(s)

What are you expecting?

Stu - of course it is impossible to know if it will success at Phase 1

That is why we take an average of Phase 1 Trials - not pick a single specific trial that supports your FUD. By quoting as low as 50% i feel that is perfectly fair and balanced.

You are not providing balance at all - you are trying to manipulate the narrative towards your agenda. Why not pick a CAR-T of AML Phase 1 that was successful????

The FACT and point i was trying to make is that, on average, Phase 1 tends to see more success that both "Pre Clinical" and "Phase 2"

Hulver - you are showing Stu too much respect

Half the time he does not know what he is posting. The only reason his posts get a response is because he tries to appear knowledgeable, when infact he is just making up stories to create FUD.

Maybe it is time to remind all the things he said about Hemo to scare people.

E.g. - issue causing CH is a much bigger and expensive issue that we thought and it may take over a year to lift...

Smart people should avoid this forum, do your research and make your choice.

Day to day fluctuations in Hemo SP are just normal movements to make a market. Given so few shares are traded and this is a small company, the SP will appear quite volatile.

If Hemo have another good year of positive development, any entry below 5 or 6p will bring handsome returns.

No Stu...

Plenty of AML studies make it past Phase 1 as you know.

The typical success rate at phase 1 is 75%. Because this is oncology and to be a bit more prudent, I quoted a range going as low as 50%

You really are quite boring

Why not post something positive for a change, surprise us.

It just goes to show the risk investing in Biotech.

The good news with Hemo, with an mCAp of £25m, a huge amount of risk has already been built in.

Only a matter of time now before Phase 1 trials begin. This will be a formal sign that Hemo CAR-T has avoided being in the 60% of drugs/therapies that do not make it out of pre clinical development.

The next benchmark to be aware of: 50-75% of drugs/therapies that enter Phase 1 trials are successful in Phase 1 trials and move on to ph2.

It's all relative Pumpky

Either way - It is not the company that Hemo are associated with

Guys, guys, guys

This is NOT the same prevail. Lilly bought a small Biotech.

Prevail Partners is a Big Investment Venture Capitalist fund - it's a private company